DISC MEDICINE INC. - COMMON STOCK

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer

19 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in Upcoming Investor Conferences

30 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Second Quarter 2024 Financial Results and Provides Business Update

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Disc Medicine Announces Underwritten Offering of Common Stock

14 Jun 2024 07:03:53 By Nasdaq GlobeNewswire

Disc Medicine Presents Positive Clinical Data Across Portfolio at the European Hematology Association (EHA) 2024 Congress

14 Jun 2024 06:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in the Jefferies Global Healthcare Conference

30 May 2024 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Multiple Presentations Across Portfolio at the European Hematology Association (EHA) 2024 Congress

14 May 2024 09:30:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in the H.C. Wainwright BioConnect Investor Conference

13 May 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports First Quarter 2024 Financial Results and Provides Business Update

09 May 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Reports Topline Results from Phase 2 AURORA Study of Bitopertin in Patients with Erythropoietic Protoporphyria (EPP)

01 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

21 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Participate in the Leerink Partners Global Biopharma Conference 2024

06 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Disc Medicine Expands Leadership Team with Appointment of Industry Veteran Pamela Stephenson, MPH as Chief Commercial Officer

26 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine Receives FDA Fast Track Designation for DISC-0974 for the Treatment of Anemia in Non-Dialysis Dependent Chronic Kidney Disease

20 Feb 2024 07:30:00 By Nasdaq GlobeNewswire

Disc Medicine Receives FDA Orphan Drug Designation for DISC-3405 for the Treatment of Polycythemia Vera

09 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Disc Medicine Strengthens Leadership Team with Appointment of Seasoned Industry Executive Jean Franchi as Chief Financial Officer, and Promotion of Jonathan Yu to Chief Operating Officer

07 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Disc Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference

03 Jan 2024 16:00:00 By Nasdaq GlobeNewswire

Disc Medicine Announces Retirement of Brian MacDonald, MB, ChB, PhD as Chief Innovation Officer and Appointment as Chair of Scientific Advisory Board

20 Dec 2023 15:30:00 By Nasdaq GlobeNewswire

Disc Presents Positive Updated Results from Phase 2 BEACON Study of Bitopertin and Other Programs at the 65th American Society of Hematology (ASH) Annual Meeting

11 Dec 2023 19:30:00 By Nasdaq GlobeNewswire

Disc Presents Initial Positive Data from Ongoing Phase 1b/2 Trial of DISC-0974 in Patients with Myelofibrosis (MF) and Anemia at the 65th American Society of Hematology (ASH) Annual Meeting

11 Dec 2023 11:00:00 By Nasdaq GlobeNewswire